{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:48:11Z","timestamp":1761518891813,"version":"build-2065373602"},"reference-count":21,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2004,10,1]],"date-time":"2004-10-01T00:00:00Z","timestamp":1096588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,10,1]],"date-time":"2004-10-01T00:00:00Z","timestamp":1096588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2004,10]]},"DOI":"10.3816\/cbc.2004.n.032","type":"journal-article","created":{"date-parts":[[2008,9,10]],"date-time":"2008-09-10T21:07:10Z","timestamp":1221080830000},"page":"287-292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Final Results of a Phase II Clinical Trial of Weekly Docetaxel in Combination with Capecitabine in Anthracycline-Pretreated Metastatic Breast Cancer"],"prefix":"10.3816","volume":"5","author":[{"given":"John R.","family":"Mackey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katia S.","family":"Tonkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheryl L.","family":"Koski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew G.","family":"Scarfe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael G.B.","family":"Smylie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil A.","family":"Joy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather-Jane","family":"Au","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dianne M.","family":"Bodnar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Soulieres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie W.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2004","series-title":"Canadian Cancer Statistics 2004","author":"National Cancer Institute of Canada","key":"10.3816\/CBC.2004.n.032_bib1"},{"issue":"5 suppl 17","key":"10.3816\/CBC.2004.n.032_bib2","first-page":"S17-1","article-title":"Chemotherapy of breast cancer: a historical perspective","volume":"24","author":"Hortobagyi","year":"1997","journal-title":"Semin Oncol"},{"key":"10.3816\/CBC.2004.n.032_bib3","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/(SICI)1097-0142(19990101)85:1<104::AID-CNCR15>3.0.CO;2-R","article-title":"Results and long term followup for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference","volume":"85","author":"Rahman","year":"1999","journal-title":"Cancer"},{"issue":"8 suppl 8","key":"10.3816\/CBC.2004.n.032_bib4","first-page":"25","article-title":"Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer","volume":"11","author":"Nabholtz","year":"1997","journal-title":"Oncology"},{"issue":"8 suppl 8","key":"10.3816\/CBC.2004.n.032_bib5","first-page":"19","article-title":"Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy","volume":"11","author":"Chan","year":"1997","journal-title":"Oncology"},{"issue":"suppl","key":"10.3816\/CBC.2004.n.032_bib6","first-page":"125","article-title":"Dose dense weekly docetaxel (Taxotere) in metastatic breast cancer","volume":"57","author":"Loeffler","year":"1999","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2004.n.032_bib7","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1023\/A:1012557528952","article-title":"Weekly docetaxel (Taxotere) in patients with metastatic breast cancer","volume":"12","author":"Stemmler","year":"2001","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2004.n.032_bib8","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1200\/JCO.2000.18.6.1212","article-title":"Docetaxel administered on a weekly basis for metastatic breast cancer","volume":"18","author":"Burstein","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2004.n.032_bib9","first-page":"244a","article-title":"Synergistic efficacy of Xeloda\u2122 (capecitabine), a new oral tumor-activated fluoropyrimidine carbamate in combination with taxanes and with 2-deoxy-2-methylidenecytidine (DMDC)","volume":"17","author":"Ishikawa","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2004.n.032_bib10","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1200\/JCO.2002.09.002","article-title":"Superior survival with capecitabine plus docetaxel combination therapy in anthracyclinepretreated patients with advanced breast cancer: phase III trial results","volume":"20","author":"O'Shaughnessy","year":"2002","journal-title":"J Clin Oncol"},{"year":"1979","series-title":"WHO handbook for reporting results of cancer treatment. Offset publication #48","author":"World Health Organization","key":"10.3816\/CBC.2004.n.032_bib11"},{"issue":"suppl","key":"10.3816\/CBC.2004.n.032_bib12","first-page":"127","article-title":"Weekly docetaxel for metastatic breast cancer; a phase II trial","volume":"57","author":"Fornasiero","year":"1999","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2004.n.032_bib13","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1200\/JCO.2001.19.15.3500","article-title":"Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial","volume":"19","author":"Hainsworth","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2004.n.032_bib14","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1200\/JCO.1998.16.6.2164","article-title":"Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer","volume":"16","author":"Hainsworth","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2004.n.032_bib15","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/JCO.1999.17.2.485","article-title":"Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer","volume":"17","author":"Blum","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2004.n.032_bib16","first-page":"1013","article-title":"Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol\/Taxotere in human cancer xenografts","volume":"4","author":"Sawada","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CBC.2004.n.032_bib17","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1001\/jama.286.3.341","article-title":"The rational clinical examination. Does this patient have clubbing?","volume":"286","author":"Myers","year":"2001","journal-title":"JAMA"},{"key":"10.3816\/CBC.2004.n.032_bib18","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1200\/JCO.2002.22.030","article-title":"Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies","volume":"20","author":"Nadella","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2004.n.032_bib19","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/annonc\/mdf036","article-title":"Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect","volume":"13","author":"Esmaeli","year":"2002","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2004.n.032_bib20","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/archopht.120.9.1180","article-title":"Docetaxel secretion in tears: association with lacrimal drainage obstruction","volume":"120","author":"Esmaeli","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.3816\/CBC.2004.n.032_bib21","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S0161-6420(02)00989-2","article-title":"Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer","volume":"109","author":"Esmaeli","year":"2002","journal-title":"Ophthalmology"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911703809?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911703809?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:08:12Z","timestamp":1761512892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820911703809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,10]]}},"alternative-id":["S1526820911703809"],"URL":"https:\/\/doi.org\/10.3816\/cbc.2004.n.032","relation":{},"ISSN":["1526-8209"],"issn-type":[{"type":"print","value":"1526-8209"}],"subject":[],"published":{"date-parts":[[2004,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Final Results of a Phase II Clinical Trial of Weekly Docetaxel in Combination with Capecitabine in Anthracycline-Pretreated Metastatic Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CBC.2004.n.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}